Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On August 9, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update.</li><li>In June 2024, the company announced that EB05 was selected by the Biomedical Advanced Research and Development Authority (BARDA) for evaluation in a U.S. government-funded clinical trial in hospitalized adult patients with acute respiratory distress syndrome (ARDS).</li><li>The data from this study could provide additional support for expanding the use of EB05, with the ultimate goal being an approval for EB05 as a standard-of-care therapy for all-cause ARDS.</li></ul>

On August 9, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update.In June 2024, the company announced that EB05 was selected by the Biomedical Advanced Research and Development Authority (BARDA) for evaluation in a U.S. government-funded clinical trial in hospitalized adult patients with acute respiratory distress syndrome (ARDS).The data from this study could provide additional support for expanding the use of EB05, with the ultimate goal being an approval for EB05 as a standard-of-care therapy for all-cause ARDS.

EDSA: EB05 Selected for BARDA-Funded Study in ARDS 

<ul><li>On May 10, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and provided a business update.</li><li> Edesa is planning to seek regulatory approval for a Phase 2 trial of its anti-CXCL10 mAb in patients with moderate-to-severe nonsegmental vitiligo.</li><li>For EB05, the company has expanded site selection activities for the Phase 3 study in acute respiratory distress syndrome (ARDS) caused by COVID-19 and has begun transitioning the day-to-day management of the trial to a new clinical research organization (CRO).</li></ul>

On May 10, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and provided a business update. Edesa is planning to seek regulatory approval for a Phase 2 trial of its anti-CXCL10 mAb in patients with moderate-to-severe nonsegmental vitiligo.For EB05, the company has expanded site selection activities for the Phase 3 study in acute respiratory distress syndrome (ARDS) caused by COVID-19 and has begun transitioning the day-to-day management of the trial to a new clinical research organization (CRO).

EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo 

United States

Edesa Biotech, Inc. operates as a clinical-stage biopharmaceutical company. The Company offers drugs for the treatment of dermatological and gastrointestinal diseases including alternatives to topical steroids. Edesa Biotech serves patients in the United States and Canada.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Edesa Biotech (EDSA US)

EDSA: EB05 Selected for BARDA-Funded Study in ARDS

On August 9, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and...

Zacks Small Cap Research

EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo

On May 10, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)